Influence of CsA treatment on adoptive transfer of immunity after allogeneic kidney transplantation in rats

Gu, Yi; Dahmen, Uta; Doebel, L.; Li, J; Dirsch, Olaf; Polywka, Susanne; Broelsch, Christoph E.

doi:10.1016/s0041-1345(00)02064-9

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In those that developed anti-HBs seroconversion, a more rapid clearance of HBsAg is also observed and the predictor of anti-HBs production is an HBV-immune donor, suggesting the possibility of adoptive immunity transfer through a liver graft. The same could be observed in rats after kidney transplantation 24 .…”

Section: Adoptive Transfer Of Immunitysupporting

confidence: 76%

Advances in immunomodulating therapy of HBV infection

Hui

Lau²

2005

Int. J. Med. Sci.

View full text Add to dashboard Cite

Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers the only means of preventing the development of these complications. However, the efficacy of these agents, in terms of loss of Hepatitis B e antigen with or without seroconversion to Hepatitis B e antibody, normalization of serum alanine transaminase levels, loss of serum HBV DNA, and improvement in liver histology can only be achieved in 20-30% of those treated. Long-term treatment with either lamivudine or adefovir dipivoxil can result in the development of drug resistant mutants leading to an increased length of treatment with additional nucleoside analogues. These limitations of the current antiviral therapies underline the need for alternative therapies. Specific and nonspecific immunotherapeutic strategies to restore effective virus-specific T cell responses in those with chronic HBV infection offers an interesting alternative approach. These immunotherapeutic therapies include the adoptive transfer of HBV immunity, pegylated interferon and therapeutic vaccine therapies.

show abstract

Section: Adoptive Transfer Of Immunitysupporting

confidence: 76%